Down regulation of vascular endothelial growth factor (VEGF) and receptors related to apoplexy in human pituitary adenomas

doi:10.3969/j.issn.1006-7795.2013.03.018

Abstract

Abstract:

Objective To investigate the expression of vascular endothelial growth factor (VEGF) and its receptor in human pituitary adenoma apoplexy.Methods Pituitary adenomas from 166 patients were included in the study. Fresh pituitary adenomas were obtained immediately after surgery and processed for histological and molecular based analyses. Real-time quantitative PCR detection system (QPCR) were used to detect mRNA expression of VEGF and its receptor. Combined with the results of pathology, immunohistochemistry and clinical data were statistically analyzed for the characteristics of packet. Results The expression levels of VEGF and VEGF-3 were significantly lower in nonfunctional pituitary adenoma group with apoplexy, is closely linked to the tumor apoplexy (P<0.05); the expression level of VEGFR-1 and VEGFR-2 was not correlated with tumor apoplexy (P>0.05). Conclusion Down regulation of VEGF and VEGFR-3 in nonfunctional pituitary adenoma was associated with tumor apoplexy. VEGF and VEGFR-3 thus has an important predictive and prognostic value in patients with pituitary tumors.

Key words: vascular endothelial growth factor (VEGF), VEGF receptor, pituitary adenoma, apoplexy

CLC Number:

R 739.41

JIA Wang, LIU Xiao, LU Runchun, JIA Guijun, NI Ming, SUN Jing, XU Zhiqing. Down regulation of vascular endothelial growth factor (VEGF) and receptors related to apoplexy in human pituitary adenomas[J]. Journal of Capital Medical University, 2013, 34(3): 416-421.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.03.018

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I3/416

References

[1] Wang C C. Wang Chungcheng’s neurosurgery [M]. Wuhan: Hubei Science and Technology Publishing Company, 2005: 620-638.

[2] Wakai S, Yamakawa K, Manaka S, et al. Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance[J]. Neurosurgery, 1982, 10(4): 437-444.

[3] Wakai S, Fukushima T, Teramoto A, et al. Pituitary apoplexy: its incidence and clinical significance (author's transl)[J]. No to shinkei, 1981, 33(3): 561-568.

[4] Findling J W, Tyrrell J B, Aron D C, et al. Silent pituitary apoplexy: subclinical infarction of an adrenocorticotropin-producing pituitary adenoma[J]. J Clin Endocrinol Metab, 1981, 52(1): 95-97.

[5] Ostrov S G, Quencer R M, Hoffman J C, et al. Hemorrhage within pituitary adenomas: how often associated with pituitary apoplexy syndrome? [J]. AJR Am J Roentgenol, 1989, 153(1): 153-160.

[6] Nawar R N, AbdelMannan D, Selman W R, et al. Pituitary tumor apoplexy: a review[J]. J Intensive Care Med, 2008, 23(2): 75-90.

[7] Carmeliet P. Angiogenesis in health and disease[J]. Nat Med, 2003, 9 (6): 653-660.

[8] Ferrara N. Vascular endothelial growth factor: basic science and clinical progress[J]. Endocr Rev, 2004, 25(4): 581-611.

[9] Arita K, Kurisu K, Tominaga A, et al. Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma[J]. Hiroshima J Med Sci, 2004, 53(2): 23-27.

[10] Fukui S, Nawashiro H, Otani N, et al. Vascular endothelial growth factor expression in pituitary adenomas[J]. Acta Neurochir(suppl), 2003, 86: 519-521.

[11] Yarman S, Kurtulmus N, Canbolat A, et al. Expression of Ki-67, P 53 and vascular endothelial growth factor(VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior? [J]. Neuro Endocrinol Lett, 2010, 31(6): 823-828.

[12] Niveiro M, Aranda F I, Peiro G, et al. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas[J]. Hum Pathol, 2005, 36(10): 1090-1095.

[13] Onofri C, Theodoropoulou M, Losa M, et al. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours[J]. J Endocrinol, 2006, 191(1): 249-261.

[14] Pizarro C B, Oliveira M C, Pereira-Lima J F, et al. Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker[J]. Neuropathology, 2009, 29(1): 40-44.

[15] Gorczyca W, Hardy J. Microadenomas of the human pituitary and their vascularization[J]. Neurosurgery, 1988, 22(1Pt1): 1-6.

[16] Turner H E, Harris A L, Melmed S, et al. Angiogenesis in endocrine tumors[J]. Endocr Rev, 2003, 24(5): 600-632.

[17] Lee J S, Park Y S, Kwon J T, et al. Radiological apoplexy and its correlation with acute clinical presentation, angiogenesis and tumor microvascular density in pituitary adenomas[J]. J Korean Neurosurg Soc, 2011, 50(4): 281-287.

[18] McCabe C J, Boelaert K, Tannahill L A, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors[J]. J Clin Endocrinol Metab, 2002, 87(9):4238-4244.

[19] Murad-Kejbou S, Eggenberger E. Pituitary apoplexy: evaluation, management, and prognosis[J]. Curr Opin Ophthalmol, 2009, 20(6): 456-461.

[20] Cheng S Y, Nagane M, Huang H S, et al. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189[J]. Proc Natl Acad Sci USA, 1997, 94(22): 12081-12087.

[21] Jung S, Moon K S, Jung T Y, et al. Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage[J]. J Neurooncol, 2006, 76(3): 257-263.

[22] Kong Y G, Ren Z Y, Su C B, et al. Expressive level of vascular endothelial growth factor in peripheral blood in patients with pituitary adenomas[J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2004, 26(2): 164-167.

[23] Jin Kim Y, Hyun Kim C, Hwan Cheong J, et al. Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas[J]. Tumori, 2011, 97(5): 639-646.

[24] Cohen A B, Lessell S. Angiogenesis and pituitary tumors[J]. Semin Ophthamol, 2009, 24(3): 185-189.

[25] Onofri C, Losa M, Uhl E, et al. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues[J]. Exp Clin Endocrinol Diabetes, 2008, 116(3): 152-157.

[26] Cristina C, Perez-Millan M I, Luque G, et al. VEGF and CD31 association in pituitary adenomas[J]. Endocr Pathol, 2010, 21(3): 154-160.

[27] Xiao Z, Liu Q, Mao F, et al. TNF-α-Induced VEGF and MMP-9 expression promotes hemorrhagic transformation in pituitary adenomas[J]. Int J Mol Sci, 2011, 12(6): 4165-4179.